RV41 Stock Chart & Stats
€5.70
€0.05(0.87%)
At close: 4:00 PM EST
€5.70
€0.05(0.87%)
Day’s Range― - ―
52-Week Range€4.74 - €9.70
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€316.11M
Enterprise Value€178.44
Total Cash (Recent Filing)€40.18M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.76
Next Earnings
Aug 06, 2026EPS Estimate
0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.31
Shares Outstanding34,737,030
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)6.28
Price to Sales (P/S)4.93
P/FCF Ratio-17.64
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€13.55Price Target Upside137.70% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)0.23
Revenue Forecast (FY)€59.71M
Bulls Say, Bears Say
Bulls Say
Revenue Growth & High Gross MarginSustained TTM revenue (~$51M) combined with ~92% gross margins indicate durable product economics for PEDMARK. High incremental margins mean additional sales largely flow to operating leverage, supporting lasting profitability as adoption expands across eligible oncology settings.
De-risked Balance Sheet (no Debt)A debt-free balance sheet with positive equity and sizable assets materially lowers financial risk. This provides strategic flexibility to fund commercial scale-up, absorb near-term cash variability, and pursue partnering or capex without near-term refinancing pressure.
Commercial Traction & HEARS Hub ScalabilityMarked QoQ infusion growth, 80% conversion/adherence and a ~4x expansion in prescriber targets suggest the HEARS hub and field model are scaling. Durable increases in conversion and adherence point to structural uptake, improving revenue predictability as clinician adoption broadens.
Bears Say
Persistent Cash BurnAlthough cash burn has improved from 2025, TTM operating and free cash flow near -$8M show the business is not yet self-funding. Sustained negative cash flow requires continued revenue acceleration or external capital, constraining optionality over the medium term.
Ongoing Losses & Negative ReturnsPersistent net losses and deeply negative ROE reflect that current returns are eroding shareholder value despite revenue gains. Until profitability and positive ROE are achieved sustainably, equity holders face dilution or prolonged unrealized value recovery risk.
Front‑loaded OpEx, Cash Seasonality & Partner RiskManagement's plan calls for materially higher, front-loaded 2026 OpEx and acknowledges Q2 cash seasonality, increasing near-term liquidity sensitivity. The missed Norgine German milestone highlights partner-dependent revenue risk, making cashflows & forecasts more contingent on execution.
Fennec Pharmaceuticals News
RV41 FAQ
What was Fennec Pharmaceuticals’s price range in the past 12 months?
Fennec Pharmaceuticals lowest stock price was €4.74 and its highest was €9.70 in the past 12 months.
What is Fennec Pharmaceuticals’s market cap?
Fennec Pharmaceuticals’s market cap is €316.11M.
When is Fennec Pharmaceuticals’s upcoming earnings report date?
Fennec Pharmaceuticals’s upcoming earnings report date is Aug 06, 2026 which is in 13 days.
How were Fennec Pharmaceuticals’s earnings last quarter?
Fennec Pharmaceuticals released its earnings results on May 14, 2026. The company reported €0.009 earnings per share for the quarter, beating the consensus estimate of -€0.039 by €0.047.
Is Fennec Pharmaceuticals overvalued?
According to Wall Street analysts Fennec Pharmaceuticals’s price is currently Undervalued.
Does Fennec Pharmaceuticals pay dividends?
Fennec Pharmaceuticals does not currently pay dividends.
What is Fennec Pharmaceuticals’s EPS estimate?
Fennec Pharmaceuticals’s EPS estimate is 0.02.
How many shares outstanding does Fennec Pharmaceuticals have?
Fennec Pharmaceuticals has 34,737,030 shares outstanding.
What happened to Fennec Pharmaceuticals’s price movement after its last earnings report?
Fennec Pharmaceuticals reported an EPS of €0.009 in its last earnings report, beating expectations of -€0.039. Following the earnings report the stock price went up 31.304%.
Which hedge fund is a major shareholder of Fennec Pharmaceuticals?
Currently, no hedge funds are holding shares in DE:RV41
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Fennec Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€13.55 (137.70% Upside)
€13.55 (137.70% Upside)
Blogger Sentiment
Bullish
DE:RV41 Sentiment 70%
Sector Average 66%
Sector Average 66%
Technicals
SMA
Positive
20 days / 200 days
Momentum
20.42%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
54.78%
Trailing 12-Months
Company Description
Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical firm. Its leading investigational drug in clinical development is PEDMARK, a specialized formulation of sodium thiosulfate. This treatment is designed to shield young cancer patients from hearing damage (ototoxicity) that can be induced by platinum-based chemotherapy. The company, which was founded in 1996, previously operated under the name Adherex Technologies Inc. before officially rebranding as Fennec Pharmaceuticals Inc. in September 2014. Its corporate headquarters are situated in Research Triangle Park, North Carolina.
RV41 Stock 12 Month Forecast
Average Price Target
€13.55
▲(137.70% Upside)
Technical Analysis
Satellos Bioscience
―
Helix BioPharma
―
―
Eupraxia Pharmaceuticals
―
ME Therapeutics Holdings, Inc.
―